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Introduction: Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the
mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the
mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or
tibolone and investigate pathways of cell proliferation in a postmenopausal primate model.
Methods: Ovariectomized female cynomolgus macaque monkeys were randomized into the following groups:
placebo (Con), oral conjugated equine estrogens (CEE), CEE with medroxyprogesterone acetate (MPA) (CEE + MPA),
and tibolone given at a low or high dose (Lo or Hi Tib). All study treatment doses represented human clinical dose
equivalents and were administered in the diet over a period of 2 years.
Results: Treatment with CEE + MPA had the greatest effect on global mRNA profiles and markers of mammary
gland proliferation compared to CEE or tibolone treatment. Changes in the transcriptional patterns resulting from
the addition of MPA to CEE were related to increased growth factors and decreased estrogen receptor (ER) signaling.
Specific genes induced by CEE +MPA treatment included key members of prolactin receptor (PRLR)/signal transducer
and activator of transcription 5 (STAT5), epidermal growth factor receptor (EGFR), and receptor activator of nuclear
factor kappa B (RANK)/receptor activator of nuclear factor kappa B ligand (RANKL) pathways that were highly
associated with breast tissue proliferation. In contrast, tibolone did not affect breast tissue proliferation but did elicit a
mixed pattern of ER agonist activity.
Conclusion: Our findings indicate that estrogen + progestin therapy results in a distinct molecular profile compared to
estrogen-alone or tibolone therapy, including upregulation of key growth factor targets associated with mammary
carcinogenesis in mouse models. These changes may contribute to the promotional effects of estrogen + progestin
therapy on breast cancer risk.
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DenosumabIntroduction
Different types of postmenopausal hormone therapy
(HT) have been widely used for more than 60 years to
alleviate symptoms of menopause and prevent associated
conditions such as osteoporosis. The primary form of
HT during much of this time has been estrogen-alone
therapy (ET) [1]. In the mid-1990s, the clinical use of
estrogen plus progestin therapy (EPT) began after several
studies demonstrated that progestins opposed the adverse* Correspondence: dougallw@amgen.com
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reproduction in any medium, provided the oreffects of ET on endometrial cancer risk [2]. These findings
helped spur a rapid increase in EPT prescriptions from less
than two million in 1995 to 24 million in 2001 [1]. At
the time, the most common type of HT used in the US
was conjugated equine estrogens (CEE) with or without
the progestin medroxyprogesterone acetate (MPA), which
together accounted for more than 60% of total HT
prescriptions [1].
Use of HT fell dramatically in 2002 after the release of
the primary results from the Women’s Health Initiative
(WHI) Estrogen + Progestin Trial [1,3]. In this large
randomized clinical trial, postmenopausal women receivingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dence of invasive breast cancer compared with those taking
the placebo [3,4]. Subsequent reports noted increased breast
cancer mortality for women taking EPT [5] and decreased
breast cancer incidence following discontinuation of EPT
[6]. These results supported prior epidemiologic studies
[7,8] but differed from the sister WHI Estrogen-Alone Trial,
in which CEE alone did not increase the incidence of
invasive breast cancer among women with a prior hyster-
ectomy [9,10]. Collectively, these studies confirmed that
the promotional effects of EPT on certain types of breast
cancer were greater than those seen with estrogen alone.
A prominent alternative to traditional menopausal HTs
used outside the US is tibolone. This unique steroidal
compound is converted in a tissue-selective manner to
estrogenic, progestogenic, and androgenic metabolites.
Estrogenic metabolites have been shown to reduce meno-
pausal symptoms and fracture risk [11,12], whereas the
progestogenic Δ-4 isomer metabolite (selectively produced
in the uterus) has been shown to provide endometrial
protection from estrogenic effects [13,14]. However,
the effects of tibolone therapy on breast cancer risk are
controversial. In a randomized clinical trial of older
postmenopausal women, tibolone therapy resulted in a
significantly lower breast cancer risk [12], whereas in a
separate clinical trial, breast cancer survivors had increased
risk of recurrence following tibolone treatment [15].
Despite numerous preclinical and clinical studies, the
mechanistic actions of different HTs on breast tissue
have not been clearly defined. In mouse models, ovarian
hormones contribute significantly to mammary gland
carcinogenesis [16]; however, differences between mouse
and human mammary gland anatomy, development, and/
or hormonal control of proliferation may limit the transla-
tional relevance of targets identified in the mouse for estro-
gen and progestogen function. Macaques are anthropoid
primates with high overall genetic coding sequence identity
to humans, including key genes related to breast cancer
susceptibility [17]. Prior work has shown close similarities
between macaque and human mammary gland biology, in-
cluding responses to exogenous estrogen and progestogen
therapies, sex steroid receptor expression, and age-related
hyperplastic and neoplastic lesions [18]. This includes a
study on aged rhesus macaques and suggests a lifetime in-
cidence of mammary gland cancer at about 6% [19], similar
to lower-risk human populations. Previous studies in this
model have also shown that the addition of a progestin to
an estrogen increases mammary gland proliferation and
density beyond that seen with estrogen alone, in support of
the later WHI findings related to breast cancer risk [20].
The primary aim of this study was to assess the effects of
long-term treatment with CEE, CEE +MPA, or tibolone
on the transcriptional profiles and signaling pathways of
the normal postmenopausal primate mammary gland. Ourmain goals were to identify specific targets associated
with hormone-induced breast proliferation and evaluate
their relations with candidate pathways known to drive
mammary carcinogenesis in mouse tumor models.
Methods
Study design and treatments
This study utilized archived tissue samples from a parallel-
arm design experiment in which 149 ovariectomized adult
female cynomolgus macaques (Macaca fascicularis) with a
mean estimated age of six to eight years were randomized
to receive one of the following five treatments for two
years: placebo (control; n = 31); CEE at 0.042 mg/kg (CEE;
n = 28); CEE +MPA at 0.167 mg/kg (CEE +MPA; n = 29);
tibolone at 0.05 mg/kg (Lo Tib; n = 30); and tibolone at 0.2
mg/kg (Hi Tib; n = 31). Dose equivalents approximated
standard HT doses of CEE (0.625 mg/day) and MPA (2.5
mg/day) in postmenopausal women, and tibolone doses
were designed to approximate 0.75 mg/day (low) and 3.0
mg/day (high) doses in women. Serum concentrations of
estrogens, MPA, and tibolone metabolites were similar to
those reported in women taking comparable therapies [21].
Treatments were administered in the control diet with
casein plus lactalbumin as the protein source and macro-
nutrient composition based on a typical human diet in the
USA [22]. Animals were housed in social groups of five ani-
mals each and fed 60 kcal/kg (plus 10% extra to account
for waste) twice daily, with drug treatments split between
the two feedings. Daily doses were scaled to 1,800 kcal of
diet (the estimated daily intake for a US woman) to account
for differences in metabolic rates between monkeys and
human subjects. All animals were considered multiparous
based on historical data from the original breeding colony
and uterine histology. Histology outcomes were described
previously [21]; no mammary gland tumors were detected.
All procedures involving macaques in this study were
conducted in compliance with State and Federal laws
and standards of the US Department of Health and Human
Services and were approved by the Wake Forest University
Animal Care and Use Committee. The facilities and la-
boratory animal program of Wake Forest University are
fully accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care.
Gene microarray analyses
Mammary gland tissues were collected during necropsy
at the end of the two-year treatment period [21], and
designated portions were snap-frozen in liquid nitrogen and
stored at −70°C for gene expression analyses. Total mam-
mary gland RNA was extracted from frozen samples using
Tri Reagent (Molecular Research Center, Cincinnati, OH,
USA), purified using RNeasy Mini kit (QIAGEN, Valencia,
CA, USA), and quantitated using a NanoDrop ND-1000
UV–vis spectrophotometer (NanoDrop, Wilmington, DE,
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using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Wilmington, DE, USA). Biotinylated cRNA samples were
prepared according to the standard Enzo Bioarray™ protocol
(Enzo Life Sciences, Farmingdale, NY, USA) and hybridized
using the standard Affymetrix (Santa Clara, CA, USA)
protocol for eukaryotic samples. Biotinylated cRNA from
each sample was hybridized to Affymetrix GeneChip
Rhesus Macaque Genome Arrays (Santa Clara, CA, USA),
washed and stained in an Affymetrix GeneChip Fluidics
Station (Santa Clara, CA, USA), and scanned with an
Affymetrix GeneChip® Scanner 3000 (Santa Clara, CA,
USA). Intensity data were extracted from scanned images
and checked for quality using Affymetrix GeneChip Oper-
ating Software and Expression Console (MAS5 algorithm;
Santa Clara, CA, USA). Microarray assays were performed
at Beckman Coulter Genomics (Morrisville, NC, USA).
Four randomly selected samples per group were run on
microarray from control, CEE, CEE +MPA, and Hi Tib
groups.
Microarray data analyses were performed using the
GeneSifter® software program (Perkin Elmer/Geospiza,
Seattle, WA, USA). Intensity data were RMA-normalized,
converted to a log2 scale, screened for heterogeneity among
samples and groups, and evaluated using supervised
analysis of variance (ANOVA) and pairwise comparisons
between treatments. Principal components analysis (PCA),
pattern navigation, cluster analysis, heat mapping, and
KEGG pathway analyses were performed on filtered data
subsets, as described in the Results section. Differences in
gene numbers altered by each treatment were compared
using either Fisher’s exact test or chi-square test. Euclidean
distances (representing the numeric difference between
treatment vectors) were calculated as part of hierarchical
clustering dendrograms using average linkage. Pathways
related to cell proliferation were evaluated using z-scores
generated in KEGG analyses; a z-score more than 2.0 was
considered significant overrepresentation of genes in a
particular pathway. All P values were corrected when
possible for multiple comparisons using the Benjamini
and Hochberg method (Padj), which derives a false discov-
ery rate estimate from the raw P-values [23]. Representation
of differentially expressed genes within specific functional
categories was evaluated using Ingenuity Pathway Analysis
software v6 (Ingenuity Systems, Redwood City, CA, USA)
using a Fisher’s exact test with Benjamini and Hochberg
correction and expressed as -log10 of the P value for gene
numbers within each treatment group. Microarray data
are publicly available on the NCBI Gene Expression
Omnibus database (accession number GSE27228).
Quantitative gene expression
Expression of genes associated with proliferation, epithelial
density, growth factor signaling, oestrogen receptor (ER)expression and activity, estrogen metabolism, and receptor
activator of nuclear factor kappa-B (RANK)/RANK ligand
(RANKL) pathway activity were measured in mammary
gland samples using quantitative real-time reverse tran-
scriptase polymerase chain reaction (qPCR). Macaque-
specific qPCR primer-probe sets for internal control genes
(glyceraldehyde-3-phosphate dehydrogenase (GAPDH);
beta-actin (ACTB)) were generated through the Applied
Biosystems Taqman Assay-by-Design service (Foster City,
CA, USA). Sources for all target primer/probe sets are
given in Additional file 1: Table S1. All probes spanned an
exon-exon junction to eliminate genomic DNA amplifica-
tion. qPCR reactions (20 μl volume) were performed on
an Applied Biosystems 7500 Fast Real-Time PCR system
(Foster City, CA, USA) using standard Taqman reagents
and thermocycling protocol [24]. Relative expression was
determined using the ΔΔCt method. The Ct values for
the control genes GAPDH and ACTB were averaged for
use in internal calibration, and premenopausal breast
tissue RNA was a reference for plate-to-plate parallel
calibration. Calculations were performed using Applied
Biosystems Relative Quantification 7500 Software v2.0.1
(Foster City, CA, USA).
Immunohistochemistry
Immunohistochemical (IHC) staining was performed on
fixed paraffin-embedded mammary gland sections. Slides
were deparaffinized, rehydrated in water, prepared by
heat-induced epitope retrieval using Diva Decloaker
(Biocare Medical, Concord, CA, USA) and Decloaking
Chamber Plus (Biocare Medical, Concord, CA, USA) at
heat and pressure cycles of 125°C for 30 and 10 seconds.
Slides were gradually cooled by replacing the retrieval
solution with deionized water and rinsed twice in wash
buffer (Dako Wash Buffer, DakoCytomation Carpinteria,
CA; five minutes) before loading on a Dako Autostainer
(Dako North America Inc, Carpinteria, CA). Sections were
blocked for endogenous peroxidases and nonspecific bind-
ing of staining reagents by sequentially incubating with 3%
hydrogen peroxidase (hydrogen peroxidase block, Thermo
Scientific Waltham, MA; 10 minutes), Avidin (Vector
Labs, Burlingame, CA; 15 minutes), Biotin (Vector Labs,
Burlingame, CA; 15 minutes), and TNB (Perkin Elmer; 20
minutes). Tris-NaCl-blocking buffer was removed and re-
placed with anti-human RANK (N-2B10.1 or N-1H8.1;
Amgen, Seattle, WA) or RANKL (M366; Amgen, Seattle,
WA) mouse monoclonal antibodies or isotype-matched
control mouse IgG (BD Pharmingen, San Jose, CA) at
concentrations of 5 μg/mL for anti-RANK and 1 μg/mL
for anti-RANKL for 60 minutes. A biotinylated, goat anti-
mouse IgG (Vector Labs, Burlingame, CA) secondary anti-
body in 10% normal human serum Tris-NaCl-blocking buf-
fer was applied at a concentration of 7.5 μg/mL followed by
a 30 minute incubation. Slides were sequentially incubated
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Elmer, Waltham, MA; 30 minutes) at a 1:1500 dilution in
TNB, tyramide signal amplification TSA (Perkin Elmer,
Waltham, MA; five minutes) at a 1:100 dilution in amplifi-
cation diluent (Perkin Elmer, Waltham, MA), and then
SA-HRP (Perkin Elmer, Waltham, MA; 30 minutes) at a
1:1500 dilution in TNB. Slides were then incubated with
diaminobenzidine chromogen (Dako, Carpinteria, CA; five
minutes), counterstained with hematoxylin (Dako, Carpinteria,
CA; 30 seconds), allowed to turn blue in tap water for two
minutes before dehydrating with ascending concentrations
of ethanol, cleared with xylene, and mounted.
The intensity of IHC staining was scored on a semiquan-
titative scale (0 = absent, 1 = weak, 2 =moderate, 3 =
intense), blinded to treatment group by a board-certified
pathologist. Incidence was scored as a positive IHC signal
(any intensity). Immunostaining of slides for Ki-67 antigen
was described previously [21]. For dual labeling experi-
ments, the following modifications to the above procedure
were performed. Antigen retrieval was performed using
Diva AR reagent (Biocare, Concord, CA; DV2004G1) at
90°C overnight in the Decloaking Chamber. Sections were
blocked as described above, incubated with either anti-
progesterone receptor PGR (Dako, Carpinteria, CA; M3569
at 1:40; 40 minutes) or anti-Ki-67 (Epitomics, Burlingame,
CA; 4203–1 at 1:400; 60 minutes), detected with Dako
Mouse or Rabbit Envision + Systems (Dako, Carpinteria,
CA, 30 minutes), and visualized by Dako DAB+ (Dako,
Carpinteria, CA, 10 minutes). Antibody staining from
the first PR/Ki-67 IHC incubation/staining were blocked
by rinsing sections in distilled water, eluting, and incubat-
ing the slides in Diva AR reagent (Biocare, Concord, CA)
at 98°C for 10 minutes. Slides were washed and blocked as
described above; followed by incubation with either anti-
RANKL (M366 at 2 μg/mL), anti-RANK (N-1H8.1 at 5
μg/mL), or mouse IgG1 isotype control (5 μg/mL) for 60
minutes. Secondary antibody incubation was performed as
described above, followed by incubation in streptavidin
alkaline phosphatase, tyramide amplification and repeat of
strepavidin alkaline phosphatase. Slides were then incu-
bated with permanent red chromogen (Dako, Carpinteria,
CA; 20 minutes), counterstained with Mayer’s hematoxylin,
washed and aqueous mounted. Histologic images were
photographed using a Nikon Eclipse E600 microscope with
a Nikon (Tokyo, Japan) DXM1200 digital camera. The
resulting images were white-balanced using Adobe
Photoshop CS software (San Jose, CA); no additional image
modifications were employed.
Statistical analyses
Data were analyzed using the SAS statistical package v9
(SAS Institute, Cary, NC, USA). All data were evaluated
for normal distribution and homogeneity of variances
among groups. Gene expression data were evaluatedusing a nonparametric Kruskal-Wallis test followed by
two-sided Wilcoxon rank sum pairwise analysis and
reported as a fold-change of control with 90% confidence
interval. One control group animal died during the course
of the study, reducing the number of control animals to
30. All pairwise P values were adjusted for the number of
pairwise tests using a Bonferroni correction. Pre-planned
pairwise tests included each treatment group versus
control and CEE +MPA versus CEE and Hi Tib groups.
Intensity of RANK/RANKL immunostaining was evalu-
ated using a one-way ANOVA with Bonferroni’s post test.
To evaluate the correlation of gene or protein expression
with IHC, data were log transformed and linear regression
analysis was performed. A two-tailed significance level of
0.05 was used for all comparisons.
Results
EPT elicits distinct effects on global gene expression
profiles
Global mammary gland expression profiles were evaluated
by microarray analysis. A total of 52,865 array probe sets
were detected at a quality score of more than 2.0. Of these,
probes for 1,534 different genes were significantly altered
at a fold change (FC) more than 1.5 and an adjusted
ANOVA P < 0.05. HTs resulted in distinct effects on mam-
mary gland gene expression. Overall transcriptional effects
were greatest for CEE +MPA and lowest for Hi Tib. For
example, CEE +MPA resulted in a greater number of
significantly altered genes versus controls (n = 1405) com-
pared with CEE (n = 437) and Hi Tib (n = 6) (P < 0.0001)
(Figure 1a). Among these genes, PCA and heatmap ana-
lysis showed modest overlap in transcriptional profiles for
CEE and CEE +MPA and a profile for Hi Tib most similar
to the control group (Figure 1b, 1c). Functional analysis
of significantly altered genes showed overrepresentation
of several categories related to cell proliferation and
cancer risk (Figure 1d). The most highly represented
functional gene category was cancer. Within this class, a
greater number of differentially regulated genes was
seen for CEE +MPA (n = 497, P < 10-34) compared with
CEE (n = 166, P = 10-14) and Hi Tib (n = 2, P = 0.01).
Other functional categories showing greater overrepre-
sentation in the CEE +MPA group included cellular
movement, signaling, and interaction (Figure 1d).
EPT increases cell proliferation and growth factor
signaling markers
Similar to global profiles, quantitative expression of specific
markers for epithelial proliferation (antigen identified by
monoclonal antibody Ki-67 (MKI67)) and density (keratin
19 (KRT19)) was highest for CEE +MPA, intermediate for
CEE, and lowest for tibolone groups compared with
placebo (Figure 2a). Treatment effects related to cell proli-





















































































































Figure 1 Global transcriptional patterns in the breast tissue following treatment with control (placebo), conjugated equine estrogens
(CEE), CEE +medroxyprogesterone acetate (MPA), and high-dose tibolone (Hi Tib). (a) Venn diagram showing greater numbers of genes
altered by CEE +MPA compared with CEE and Hi Tib. (b) principal component analysis and (c) heatmap of differentially regulated genes showing
greater overlap between Con and Hi Tib groups and the CEE +MPA and CEE groups. (d) Functional categories of significantly altered transcripts
showing overrepresentation of genes involved in cancer and several related classes. mRNA profiles were determined by microarray analysis. All
diagrams correspond to significantly altered transcripts with fold-change of more than 1.5 versus control group in at least one group, adjusted
analysis of variance (ANOVA) P < 0.05, and quality more than 2.
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transforming growth factor (TGF)-beta pathway, which
was significantly overrepresented among downregulated
genes. On microarray analysis, Jak/Stat and ErbB-related
genes related primarily to signal transducer and activator
of transcription 5 (STAT5) and epidermal growth factor
receptor (EGFR) signaling pathways, respectively. On
qPCR, expression of key molecules within thesepathways was highest for CEE +MPA treatment, show-
ing similar overall expression patterns to that seen for
MKI67 (Figure 2b, 2c) and high correlation for individual
markers, particularly STAT5A and amphiregulin (AREG)
(R > 0.7, P < 10-20 for both) [see Additional file 2: Figures
S1a, S1b]. In contrast, no significant treatment effects
were seen on qPCR for individual markers of TGF-beta















































































































































































Figure 2 Hormone therapy effects on gene markers related to mammary gland proliferation. (a) markers included cell proliferation
(MKI67) and epithelial density (KRT19) and genes involved in the following signaling pathways; (b) STAT5; (c) EGFR; and (d) TGF-beta. mRNA levels
were determined by quantitative PCR. Vertical lines indicate 90% confidence interval. Letters indicate significant differences compared with
control (P < 0.05a, P < 0.01b, P < 0.001c) and conjugated equine estrogens plus medroxyprogesterone acetate (CEE +MPA), (P < 0.01d, P < 0.001e)
groups.
Wood et al. Breast Cancer Research 2013, 15:R62 Page 6 of 16
http://breast-cancer-research.com/content/15/4/R62Adding a progestin to ET inhibits ER activity
We next examined whether patterns of ER activity were
associated with treatment differences in proliferation and
growth factor expression. Treatment with CEE markedly in-
duced gene markers of ER activity, whereas the addition of
MPA completely or partially antagonized this effect (de-
pending on the marker). For example, CEE increased trefoil
factor 1 (TFF1) expression by 82-fold, whereas CEE +MPA
was not different from placebo (Figure 3a). For other ER-
induced markers such as progesterone receptor (PGR) and
growth regulation by estrogen in breast cancer 1 (GREB1),
the addition of MPA blocked 75% and 71% of CEE-induced
expression, respectively. This pattern was also present on
microarray analysis, where the primary cluster of genes dif-
ferentially altered between CEE and CEE +MPA groupswere related to ER signaling. The gene cluster included
TFF1, PGR, GREB1, and other ER-sensitive genes such as
insulin-like growth factor binding protein 1 (IGFBP1),
breast carcinoma amplified sequence, and fibulin. Tibolone
had a mixed pattern of effects on ER activity, inducing PGR
and GREB1 (P < 0.001 for both compared with control) but
not TFF1 at the higher dose (Figure 3a). Treatment effects
on ER activity were not directly associated with changes in
expression of ER-alpha (ESR1), ER-beta (ESR2) (Figure 3b),
or key genes related to estradiol metabolism (Figure 3c, 3d).
However, ER immunolabeling was lower for ESR1 following
CEE +MPA but not CEE as described previously [25]. In
contrast to growth factors, markers of ER activity showed
modest (PGR and GREB1) or no (TFF1) significant correl-






































































































































































Figure 3 Hormone therapy effects on gene markers related to ER expression and activation. (a) Hormone therapy effects on gene
markers related to oestrogen receptor (ER) activation; (b) ER expression; (c) estradiol synthesis and bioactivation; and (d) estradiol deactivation.
mRNA expression levels were determined by quantitative PCR. Vertical lines indicate 90% confidence interval. Letters indicate significant
differences compared with control (P < 0.05a, P < 0.01b, P < 0.001c) and conjugated equine estrogens plus medroxyprogesterone acetate (CEE +
MPA) (P < 0.01d, P < 0.001e) groups.
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The main transcriptional pattern among genes altered
by the Hi Tib dose related to ER signaling; no other clear
patterns were noted. Of the 24 identified genes with more
than three FC and P < 0.05 compared with control, 20
genes were upregulated. Among these, there were seven
known ER-sensitive genes (PGR, GREB1, stanniocalcin 2
[STC2], secretoglobin family 1D member 2 [SCGB1D2],
kallikreins 11 [KLK11] and 12 [KLK12], and IGFBP1); two
genes involved in steroid metabolism (cytochrome p450
family 2 subfamily A polypeptide 7 [CYP2A7] and 3-beta-
hydroxysteroid dehydrogenase Δ-5-Δ-4 isomerase type II
[HSD3B2]); two secretoglobins (SCGB3A1 and SCGB1D2);
and three peptidases (disintegrin and metalloproteinasewith thrombospondin motifs 8 [ADAMTS8], KLK11, and
KLK12). Notably, isoforms of HSD3B are the primary
enzymes driving production of the progestogenic delta-4
tibolone metabolite [13]. Despite a 6.5 FC increase in
HSD3B2 expression in the Hi Tib group, no markers of
progestogenic activity were noted.
EPT increases RANK/RANKL pathway expression
The RANK pathway exhibits crosstalk with both STAT5
[26] and EGFR [27] signaling and contributes to proges-
togen-induced cell proliferation in the mouse mammary
gland [28,29]. Mouse mammary expression of RANKL is
increased substantially after progestin treatment [30],
and increased RANK expression is observed at ductal side
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morphogenesis [31]. To further explore hormonal regula-
tion of this pathway in the primate mammary gland, we
evaluated ET and EPT effects on expression of mRNAs en-
coding RANK, RANKL, and the endogenous inhibitor of













































a : P < .05 relative to Con
b : P < .001 relative to Con
c : P < .01 relative to CEE
RANK/OPG
RANKL/OPG
a : P < .05 relative to Con
b : P < .01 relative to Con
c : P < .001 relative to Con
d : P < .05 relative to CEE+MPA
b
Figure 4 Hormone therapy effects on gene markers of RANK/RANKL
inhibitor of RANKL signaling (OPG) and (b) ratios between these markers. m
(a) relative means or as (b) ratios of RANK/OPG or RANKL/OPG. Vertical lines
differences between groups as indicated.differences in RANK, RANKL, or OPG expression were
noted in analysis by microarray. By qPCR, treatment with
CEE alone did not result in significant changes in RANK,
RANKL, or OPG expression (Figure 4a), whereas treatment
with CEE +MPA resulted in a significantly higher expres-








signaling. (a) mRNA expression of RANK, RANKL, and the endogenous
RNA levels were determined by quantitative PCR and expressed as
indicate 90% confidence interval. Letters indicate significant
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Treatment with CEE +MPA also increased RANKL mRNA
more than three-fold versus control and the differences be-
tween RANKL mRNA levels after CEE +MPA versus CEE
treatment were statistically significant (P < 0.01). Analysis of
RANKL mRNA changes was confounded by one animal in
the CEE-treated cohort which had more than 50-fold higher
levels of RANKL mRNA than all other animals. Treatment
with CEE +MPA resulted in greater ratios of RANK and
RANKL to OPG compared with control (P < 0.001 and P <
0.01, respectively; Figure 4b) and greater ratio of RANKL to












































Figure 5 Regression analysis for expression of the proliferation marker
MKI67 and the RANKL/OPG mRNA ratio was only observed within the conjuga
group and not in the control or CEE groups. The strongest correlation of MKI6Although RANKL mRNA levels did not correlate with
MKI67 [see Additional file 3: Figure S2a], the ratios of
RANKL:OPG and RANK:OPG expression showed a signifi-
cant positive association with MKI67 (Figure 5), with the
strongest correlations observed in the CEE +MPA group
(R = 0.59, P= 0.0007 and R = 0.64, P = 0.0002, respectively).
The RANK/OPG ratio expression also showed a significant
positive association with STAT5A (R = 0.69, P < 0.0001) and
KRT19 (R = 0.55, P < 0.0001), whereas RANKL/OPG ratio
showed significant positive, yet modest, correlations with
STAT5A and KRT19 (R = 0.35, P = 0.0008 and R = 0.29,
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MKI67 versus RANKL/OPG or RANK/OPGmRNA ratios. Correlation of
ted equine estrogens plus medroxyprogesterone acetate (CEE +MPA)
7 and RANK/OPG mRNA ratio was observed in the CEE +MPA group.
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expression in the mammary gland
We next utilized IHC with monoclonal antibodies against
huRANKL or huRANK to verify that the observed changes
in mRNA expression were translated into protein and to
determine precise cellular localization for each protein.
RANKL protein was not observed within the mammary
epithelium of postmenopausal monkeys in the control
group but was selectively increased in the CEE +MPA
group (Figures 6a; 7a, b). In contrast, RANK protein in
the mammary gland was prevalent across all groups
(>50% of monkeys in each group; Figures 6b; 7a) with
a modestly lower composite score for the CEE and
CEE +MPA groups compared with control (P < 0.05
and P < 0.01, respectively; Figure 7b). RANKL protein
expression was observed exclusively within luminal
epithelial cells of ducts and lobuloalveolar structures, such
that RANKL-positive cells were adjacent to RANKL-
negative cells (Figure 6a). Dual immunostaining of samples
from CEE +MPA-treated monkeys indicated that RANKL
protein was localized in PGR-expressing luminal epithelial
cells of ducts and lobuloalveolar structures [see Additional
file 5: Figure S4], similar to what has been described in mice
[28] and humans [32]. Expression of RANK protein was
not uniform within the mammary gland, showing segmen-
tal foci of positive staining predominately within ducts
and lobuloalveoli (Figure 6b). Furthermore, RANK protein
expression was observed in basal cells and other epithelial
cells that extended from the basal compartment to the
lumen. Immunostaining of both RANK and RANKL was
predominately limited to mammary epithelium, with rare
expression in infiltrating cells (presumed lymphocytes).
Staining was cytoplasmic and membranous for both RANK
and RANKL, often with a granular cytoplasmic appearance
for RANKL. This cellular distribution of RANK and
RANKL protein within the monkey mammary gland was
similar to that observed in mice [28,31] and tissue from
normal human breast (Branstetter and Dougall, manuscript
in preparation).
RANKL and RANK protein expression is associated with
mammary epithelial cell proliferation
The intensity of RANKL protein expression determined
by IHC showed a significant positive correlation with
RANKL mRNA within the CEE +MPA group (R = 0.62,
P = 0.0004) but not the control and CEE groups [see
Additional file 6: Figure S5]. Previous analysis using Ki-67
IHC defined a mammary epithelial proliferative response
specifically in the CEE +MPA group, with the majority of
labeling in the lobuloalveolar compartment and minimal
Ki-67 increases observed in large ducts [21]. Here, RANKL
protein expression within the CEE +MPA group was
significantly correlated with the degree of proliferation
as determined by Ki-67 IHC in both alveoli (R = 0.48,P = 0.009; Figure 8a) and ducts (R = 0.6, P = 0.002;
Figure 8b); there were no significant positive correlations
of RANKL protein and Ki-67 IHC within control or CEE-
treated groups (Figure 8a, 8b). RANK protein and mRNA
were not significantly correlated in any group [see
Additional file 6: Figure S5]. Although the intensity of
RANK protein was not correlated with the degree of
proliferation in any group [see Additional file 7: Figure S6],
dual labeling of RANK and Ki-67 was observed in a subset
of proliferating breast epithelial cells from CEE +MPA-
treated monkeys. Segmental foci of breast epithelium that
stained positively for RANK were also frequently positive
for Ki-67 whereas RANK-negative regions of the same
breast tissue often had few or no Ki-67 labeled cells [see
Additional file 8: Figure S7]. In addition, clear examples
of individual cells positive for both RANK and Ki-67
were observed in ducts and lobuloalveolar structures
[see Additional file 8: Figure S7].
Discussion
The addition of a progestin to ET is associated with
increased breast tissue proliferation [33], mammographic
density [4], and breast cancer risk in postmenopausal
women [4,7,8]. Molecular mechanisms driving these effects
are not clearly defined. In this study we show that adding
the progestin MPA to CEE dramatically altered the
mRNA profile in the normal primate mammary gland.
This change was associated with greater mammary
gland proliferation, decreased markers of ER activity,
and increased markers of growth factor signaling. Many
of the progestin-dependent changes observed here are
also seen in the mouse mammary gland and have been
associated with mammary carcinogenesis. These find-
ings identify key differences among common types of
menopausal HTs and highlight specific pathways rele-
vant to hormonal promotion of mammary epithelial
cell growth.
Our results show clear differences between ET and
EPT effects on breast tissue and support the hypothesis
that EPT increases cell proliferation beyond that of ET
alone due in part to specific growth factor signals. Three
primary progestin-regulated pathways were identified in
this study: prolactin receptor (PRLR)/STAT5, EGFR, and
RANK/RANKL. The STAT5 pathway has been shown to
mediate PRLR activity and regulate mammary gland
development, differentiation, and proliferation [26,34],
whereas EGFR is a central growth factor pathway in
mammary gland development and a subset of breast
cancers [35]. Both PRLR/STAT5 and EGFR pathways
are also known targets of progestogen action in the
mouse mammary gland [36,37].
RANK/RANKL is the third pathway selectively modified
by the combination of CEE +MPA. This pathway has
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Figure 6 Expression and localization of RANKL and RANK protein within the mammary gland. (a,b) Representative images of RANKL and
RANK immunohistochemical staining in control and conjugated equine estrogens plus medroxyprogesterone acetate (CEE +MPA) groups. There
is no detectable staining for RANKL in the control group but RANKL protein is clearly evident exclusively within the luminal epithelial cells of the
lobuloalveolar and ductal epithelium in the CEE +MPA group. RANKL was not detected within myoepithelial, stromal, or infiltrating immune cells.
RANK expression was observed in both ductal and lobuloalveolar structures in all groups. RANK protein was predominately observed in basal cells
in close proximity to the basement membrane and also in some epithelial cells, which extended from the basement matrix/basal layer to the
lumen. The observed staining of intraluminal secretory material using the RANK antibodies was due to non-specific binding to proteinaceous
material in serum (data not shown).





















a : P < .05 relative to Con
b : P < .01 relative to Con
c : P < .001 relative to Con




Con 28 82.1% 0%
CEE 26 69.2% 11%
CEE+MPA 28 60.7% 71.4%





Figure 7 Hormone therapy effects on incidence of expression
and intensity of IHC staining for RANK and RANKL. (a)
Incidence score for RANK or RANKL immunohistochemical (IHC)
positivity in each group. (b) Mean composite IHC score +/−
standard error of the mean in each treatment group. Letters
indicate significant differences versus control (P < 0.05a, P < 0.01b,

































































Figure 8 Correlation of RANKL protein expression with Ki-67
protein expression. Regression analysis for expression of the
proliferation marker Ki-67 (immunohistochemical (IHC)) versus RANKL
protein (IHC) in (a) lobuloalveolar or (b) ductal cells. Correlation
between RANKL IHC score and percent Ki-67 positive cells is observed
in conjugated equine estrogens plus medroxyprogesterone acetate
(CEE +MPA) treated animals (R = 0.48, P = 0.009 for lobuloalveolar
epithelia, R = 0.6, P = 0.002 for ductal epithelia). The majority of animals
within the control and CEE groups (100% and 88%, respectively) did
not express RANKL by IHC, precluding an accurate correlation analysis
between RANKL and Ki-67 in these groups.
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and survival of bone-resorbing osteoclasts [38]. Modulation
of the latter mechanism is the basis for the development
of the fully human monoclonal antibody to RANKL,
denosumab, recently approved for the prevention of
skeletal-related events in patients with bone metastases
from solid tumors [39]. Analysis of RANK- and RANKL-
knockout mice revealed defective mammary alveologenesis
[40], which resembled the mammary morphogenic defect
observed in PGR-knockout mice [41]. Transcription of
RANKL is rapidly induced upon progesterone exposure in
mice [30] and co-localized with PGR within “transmitter”
ER/PGR-positive luminal mammary epithelial cells [42].
Subsequent studies have shown that RANKL is an essential
paracrine mediator of progesterone function in the mouse
mammary gland, leading to both mammary epithelial
proliferation [43] and the transient expansion and increased
regenerative potential of mammary stem cells [44,45] dur-
ing pregnancy and the estrous cycle. Importantly, thesefunctionalities are not limited to normal mammary mor-
phogenesis and observations in rodent models have now
shown that RANKL, via activation of RANK within mam-
mary epithelium, mediates progesterone-dependent mam-
mary tumor formation [28,29].
Currently, it is unclear whether the RANK/RANKL
pathway functions similarly in human breast tissue. In
the current study, we show that key components of the
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mammary gland and modulated by long-term EPT expos-
ure at clinically relevant doses. Protein expression patterns
of RANKL and RANK protein were highly similar to those
seen in the mouse [28] and human mammary gland (data
not shown) [32]. In each species, RANKL protein is focally
expressed in discrete luminal epithelial cells of the ducts
and lobules often separated by adjacent RANKL-negative
cells. Dual immunolabeling revealed that RANKL protein
expression was highly colocalized within PGR-positive
luminal epithelial cells in this study, similar to what has
been recently described in mice and humans [28,32]. In
contrast, RANK protein is segmentally expressed, sporad-
ically in alveoli and often in cells located along the basal
aspect of ducts but also in epithelial cells that extend from
the basal compartment to the lumen. Similar to observa-
tions in mice, RANKL protein levels within the mammary
epithelium of macaques were clearly elevated upon expos-
ure to estrogen with a progestin but not estrogen alone. In
the CEE +MPA group, we also observed decreased mRNA
expression levels of OPG, the negative regulator of RANKL,
thereby increasing the ratio of either RANKL/OPG or
RANK/OPG. Increased RANKL protein expression was
positively associated with increased ductal and alveolar
proliferation driven by EPT. RANK protein was colocalized
with Ki-67 in a subset of cells, suggesting that RANK-
expressing breast cells directly respond to the RANKL
signal and comprise at least part of the proliferative
component after progestin exposure. Altogether, multiple
mechanisms of hormone-dependent control contributing
to the net increase in RANKL signal were identified and
shown to be positively associated with increased epithelial
proliferation (MKI67) and density (KRT19), suggesting that
this pathway may be utilized across mammalian species
for progestogen-dependent breast proliferation.
In premenopausal women, ovarian-produced progester-
one may also contribute to the established relation between
breast cancer risk and number of menstrual cycles or
reproductive history [46], potentially via increased breast
proliferation [47] and the non-proliferative expansion of
normal or transformed mammary stem cells [44,45,48].
Using a candidate gene approach, a recent study identified
RANKL, c-Kit, and gene signatures representing MaSC or
luminal progenitors as each being associated with younger
age at breast cancer diagnosis [49]. Although the relative
contribution of RANKL mRNA from normal breast versus
tumor tissue was not specified in this analysis of patients
with breast cancer, the authors concluded that the strong
correlation of these gene sets (including RANKL expres-
sion) was independent of breast cancer subtype and instead
represented unique biological pathways common to breast
cancer in young women and perhaps related to the poor
prognosis in these patients. Given the present evidence,
the increased mammary mitogenesis observed duringthe progesterone-dominant luteal phase of the human
menstrual cycle [47] could involve an operative role of
RANKL. Recent gene expression analysis of fine-needle
aspirates of human breast tissue demonstrating significant
upregulation of RANKL mRNA during the luteal phase
[50] is consistent with this notion. In fact, a recent publi-
cation [32] has demonstrated that RANKL levels in the
human breast are correlated with serum progesterone
levels. Furthermore, RANKL was not only sufficient to in-
duce human breast cell proliferation but was also required
for progesterone-induced breast cell proliferation. These
data, with observations presented in this primate study,
suggest that the increased RANKL signal in human breast
tissue is a consequence of progestogen exposure in post-
menopausal women or luteal phase ovarian progesterone
in premenopausal women. Moreover, this increased RANKL
may be correlated with the proliferative status and overall
density of the mammary epithelium and contribute to
hormone-dependent breast tumor formation.
The three signaling pathways identified here as being
selectively increased by EPT all exhibit signaling cross-talk
that may be functionally important in breast cancer. Prior
studies have shown that the induction of RANKL by MPA
requires expression of PRLR and that prolactin signaling
is necessary for nuclear translocation of STAT5A after EPT
[29,51]. These findings also indicate that the interferon-
gamma responsive elements identified within the RANKL
promoter are essential for activation of the JAK2/STAT5A
response [51] and potentially important for progestogen-
dependent increases. Other studies have shown that nuclear
phosphorylated STAT5A is co-localized with PGR and
RANKL in cells after EPT [26], further suggesting that
progestogen-dependent increases in RANKL transcription
may be governed at the RANKL promoter, at least in part,
by a complex of PGR and STAT5A, similar to that ob-
served with the β-casein promoter [52]. Finally, EGFR
ligands have been shown to strongly decrease OPG ex-
pression in an EGFR-dependent manner [27] and activate
STAT5A in mammary tissue [53]. Collectively, these data
support a model in which progestogen activity in breast
tissue may increase RANKL protein expression either
directly, or indirectly, via PRLR/STAT5 signaling, whereas
OPG protein expression may be decreased via EGFR
signaling. Future studies are warranted to determine if
multifactorial convergences of the PRLR/STAT5, EGFR,
and RANK/RANKL pathways may contribute to breast
cancer risk.
Unlike EPT, tibolone did not show a clear induction of
mRNA markers in breast tissue related to growth factor
signaling. This finding is consistent with the lack of
increased mammary epithelial Ki-67 labeling reported
previously [21] and the lack of increased breast cancer risk
among older postmenopausal women receiving tibolone in
the LIFT clinical trial [12]. In contrast, tibolone treatment
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increased risk of recurrence among breast cancer patients
with ER-positive tumors and vasomotor symptoms [15].
Sub-group analysis among women receiving adjuvant endo-
crine therapy indicated that tibolone interference was
greater for aromatase inhibitors (which decrease systemic
and local estrogen) than for tamoxifen (which blocks ERs).
The authors of the study suggest that these findings point
to potential ER agonist effects of tibolone on occult,
estrogen-sensitive metastases [15]. Results from the current
study provide limited support for this idea, showing modest
estrogenic effects of tibolone on some gene markers of ER
activity but no clear progestogenic effects or activity related
to specific growth factor pathways.
Conclusions
Minimizing breast cancer risk by mitigating potential
adverse effects of hormonal agents is a central challenge in
women’s health. Results of this study expand the current
understanding of transcriptional patterns and signaling
pathways underlying HT effects in mammalian breast
tissue. Findings presented here identify PRLR/STAT5,
EGFR, and RANK/RANKL as molecular pathways that
may be relevant to increased breast tissue proliferation,
mammographic density, and breast cancer risk in postmen-
opausal women taking EPT. These pathways are potential
targets for assessing and preventing progestogen-associated
risk, and this information should help inform clinical strat-
egies to better prevent hormone-associated breast cancer
and recurrence.Additional files
Additional file 1: Table S1. Primer/probe sets for target genes
evaluated by quantitative PCR.
Additional file 2: Figure S1. Regression analysis for expression of the
proliferation marker MKI67 and markers of STAT5, epidermal growth factor
receptor (EGFR), and estrogen receptor (ER) signaling pathways. (a) MKI67
mRNA versus STAT5 markers; (b) MKI67 mRNA versus EGFR markers; and (c)
MKI67 mRNA versus ER markers. Across all groups, the strongest positive
correlations were observed between MKI67 versus STAT5A, PRLR, amphiregulin
(AREG), and transforming growth factor-alpha (TGFA) (P< 0.0001 for all).
Additional file 3: Figure S2. Regression analysis for MKI67 versus RANKL
and RANK. (a) RANKL mRNA versus MKI67. (b) RANK mRNA versus MKI67.
Significant positive correlations were observed between RANK versus
MKI67 (R = 0.48, P < 0.0001).
Additional file 4: Figure S3. Regression analysis for STAT5A or a marker for
breast density (KRT19) versus RANKL/OPG or RANK/OPG mRNA ratios. (a)
RANKL/OPG mRNA ratio versus STAT5A. (b) RANK/OPG mRNA ratio versus
STAT5A. (c) RANKL/OPG mRNA ratio versus KRT19. (d) RANK/OPG mRNA ratio
versus KRT19. Significant positive correlations were observed between RANK/
OPG versus STAT5A (R = 0.69, P< 0.0001) and RANK/OPG versus KRT19 (R = 0.55,
P< 0.0001). RANKL/OPG versus STAT5A or KRT19 show modest positive
correlations (R = 0.35, P= 0.0008 and R = 0.29, P= 0.006, respectively).
Additional file 5: Figure S4. RANKL is localized in PGR-positive mammary
luminal epithelial cells. Representative examples of immunohistochemical co-
labeling of RANKL and PGR in breast tissue from conjugated equine
estrogens plus medroxyprogesterone acetate (CEE +MPA) treated monkeys.RANKL is red and PGR is brown. (a) RANKL and PGR labeling in breast duct
(40X); (b) RANKL and PGR labeling in lobuloalveolar structure (60X). RANKL
and PGR protein is clearly evident exclusively within the luminal epithelial
cells of the lobuloalveolar and ductal epithelium. Cytoplasmic and membrane
RANKL expression is localized in PGR expressing cells.
Additional file 6: Figure S5. Correlation of either RANKL or RANK
protein expression with corresponding mRNA expression. (a) RANKL
protein immunohistochemical (IHC) score versus RANKL mRNA. A
significant positive correlation was observed in the conjugated equine
estrogens plus medroxyprogesterone acetate (CEE + MPA) group
(R = 0.62, P = 0.0004) only. The majority of animals within the control and
CEE groups (100% and 88%, respectively) did not express RANKL by IHC,
precluding correlation analysis between protein and mRNA expression in
these groups. (b) RANK protein IHC score versus RANK mRNA. There were
no significant correlations in any group.
Additional file 7: Figure S6. Correlation of RANK protein expression with
Ki-67 protein expression. RANK composite immunohistochemical (IHC) score
versus log10 Ki-67 positive cells (%) in (a) lobuloalveolar or (b) ductal cells. No
correlation between RANK IHC score and Ki-67 positive cells (%) was observed.
Additional file 8: Figure S7. Dual labeling of RANK protein expression
and Ki-67 in breast epithelium from conjugated equine estrogens plus
medroxyprogesterone acetate (CEE +MPA) treated monkeys. (a to d)
Representative examples of immunohistochemical (IHC) co-labeling of RANK
and Ki-67 in breast tissue from CEE +MPA-treated monkeys. RANK is red and
Ki-67 is brown. Nuclear staining of Ki-67 was observed in a subset of cells
with cytoplasmic and membrane expression of RANK. Low magnification
views (a, 10X; b, 40X) of breast tissue demonstrate segmental foci of breast
epithelium stained positively for RANK that were also frequently positive for
Ki-67 (as circumscribed by dashed lines). Conversely, RANK-negative regions
of the same breast tissue often had few or no Ki-67 labeled cells. (c and d)
Higher magnification views (60X) show clear examples of individual cells
positive for both RANK and Ki-67 in (c) ducts and (d) lobuloalveolar structures.
Individual ductal cells positive for both Ki-67 and RANK are indicated by
arrows. In the example of staining in lobuloalveolar tissue, the majority of this
particular segment stains positively for RANK (similar to that shown in
Figure 6b and Additional file 8: Figure S7a, b) with Ki-67 staining in a subset
of these RANK-positive cells.
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